The First Large‐Scale Nucleic Acid Amplification Testing (NAT) of Donated Blood Using Multiplex Reagent for Simultaneous Detection of HBV, HCV, and HIV‐1 and Significance of NAT for HBV
The First Large‐Scale Nucleic Acid Amplification Testing (NAT) of Donated Blood Using Multiplex Reagent for Simultaneous Detection of HBV, HCV, and HIV‐1 and Significance of NAT for HBV
复制标题
首次使用多重试剂对捐献血液进行大规模核酸扩增检测 (NAT)，同时检测 HBV、HCV 和 HIV-1 以及 NAT 对 HBV 的意义
DOI：
--
复制
发表时间：
2001
影响因子：
2.6
通讯作者：
Kusuya Nishioka
中科院分区：
文献类型：
--
作者：
H. Ohnuma;Takeshi Tanaka;A. Yoshikawa;H. Murokawa;K. Minegishi;R. Yamanaka;Hisao Yugi Lizuka;M. Miyamoto;Shuhei Satoh;S. Nakahira;T. Tomono;T. Murozuka;Y. Takeda;Yasushi Doi;H. Mine;Shigeki Yokoyama;Toru Hirose;Kusuya Nishioka
日本红十字会输血服务中心首次在全国范围内对自愿捐献的血液进行了B型肝炎病毒（HBV）、丙型肝炎病毒（HCV）和人类免疫缺陷病毒1型（HIV-1）的核酸扩增检测（NAT），该检测是在血清学预筛选后和细胞成分和血浆分离前进行的。从2000年2月1日至2001年4月30日，在献血后24小时内，使用多重HBV/HCV/HIV-1输血试剂（包括短保质期血小板），通过NAT在50份样本的小样本池中筛选了6，805，010单位血清学阴性献血者的标本。其中，筛选出112例HBV DNA阳性、25例HCV RNA阳性和4例HIV 1 RNA阳性，我们可以预防这些NAT阳性单位的输血。HBV DNA亚型/基因型有adr/C、adw/A、adw/B、adw/C、ayr/C和ayw/D，以adr/C为主。过夜EIA阴性率为61.6%（69/112）。HBV NAT阳性样本中有63例携带的病毒载量低于104拷贝/mL，其中92.1%（58/63）的样本经过夜EIA检测为阴性。回顾性和前瞻性随访研究获得的6例HBV病毒生长曲线在血清学窗口期早期呈指数直线，血清学窗口期HBV生长（10倍增长）的对数时间在4.6 ~ 7.6天之间。在样本池中使用高灵敏度试剂进行NAT筛查有助于从输血中排除低水平HBV和HBV突变体的血液单位。
The first nationwide nucleic acid amplification testing (NAT) for hepatitis B virus (HBV), hepatitis C virus (HCV), and human immunodeficiency virus type 1 (HIV‐1) of voluntarily donated blood after serological pre‐screening and before release of cellular components and plasma for fractionation was implemented by the Japanese Red Cross Blood Transfusion Services. From February 1, 2000 to April 30, 2001, specimens from 6,805,010 units of serologically negative donation were screened in minipools of 50 samples within 24 hr after blood donation by NAT using multiplex HBV/HCV/HIV‐1 reagent for blood transfusion including short shelf‐life platelets. Among them, 112 HBV DNA‐positives, 25 HCV RNA positives and 4 HIV‐1 RNA positives were screened out and we could prevent transfusion of these NAT positive units. Subtypes/genotypes of HBV DNA, adr/C, adw/A, adw/B, adw/C, ayr/C and ayw/D were found and adr/C was predominant. A total of 61.6% of them (69/112) were negative by overnight EIA. Sixth three of HBV NAT‐positive samples carried virus loads less than 104 copies/mL and 92.1% of them (58/63) were negative by overnight EIA. The virus growth curves of HBV in 6 cases obtained by retrospective and prospective follow‐up study showed exponential straight lines in the early stage of serological window periods and the log times of HBV growth (10 fold increase) in serological window period were between 4.6 and 7.6 days. NAT screening with highly sensitive reagents in pool of specimens is useful to exclude blood units with low level of HBV and HBV mutants from blood transfusion.
影响因子：
56.9
作者：
Guidotti, LG;Rochford, R;Chisari, FV
通讯作者：
Chisari, FV